boost
arsen
comput
drug
repurpos
coronaviru
diseas
world
health
emerg
call
scientist
unpreced
huge
investig
effort
urgent
answer
key
question
natur
origin
viru
molecular
chang
account
aggress
mortal
human
immunolog
respons
specif
activ
long
acquir
immun
last
recov
peopl
suscept
expos
popul
base
genet
background
patient
treat
angiotensinconvert
enzym
ace
inhibitor
increas
risk
infect
top
best
therapeut
option
readi
help
cure
patient
patient
suffer
sever
diseas
hospit
overwhelm
worldwid
global
mortal
rate
goe
without
say
new
efficaci
treatment
immedi
need
new
intervent
clinic
trial
treatment
involv
use
antivir
drug
previous
use
treat
ebola
viru
known
remdesivir
combin
two
antivir
ritonavir
lopinavir
previous
approv
treat
hiv
infect
addit
activ
clinic
trial
involv
use
drug
approv
differ
therapeut
indic
case
exampl
fdaapprov
antimalari
drug
chloroquin
hydroxychloroquin
owe
abil
interfer
basic
cellular
pathogenet
mechan
ii
monoclon
antibodi
receptor
might
help
reduc
abnorm
inflammatori
respons
upon
cytokin
storm
thu
improv
organ
function
patient
recycl
strategi
base
reus
approv
drug
commonli
refer
drug
repurpos
larg
success
demonstr
exampl
repurpos
treatment
cancer
human
diseas
drug
repurpos
modern
therapeut
strategi
substanti
reduc
risk
drug
develop
cost
emerg
shorten
time
gap
identif
potenti
use
drug
treatment
patient
owe
avail
larg
amount
safeti
toler
pharmacokinet
pharmacodynam
clinic
data
exist
drug
inde
use
drug
differ
therapeut
indic
also
refer
offlabel
use
take
advantag
phase
iii
trial
defin
potenti
maximum
toler
dose
predict
potenti
side
effect
support
therapi
thu
presenc
preliminari
clinic
efficaci
observ
strong
pharmacolog
rational
possibl
immedi
test
exist
drug
novel
therapeut
indic
human
patient
efficaci
drug
repurpos
reach
drug
repurpos
often
result
serendip
might
also
result
experiment
drug
screen
identif
target
similar
among
differ
diseas
involv
common
pathogenet
mechan
among
differ
diseas
similarli
scientif
base
motiv
abovedescrib
repurpos
trial
ongo
worldwid
cure
togeth
current
approach
multipl
incis
investig
step
immedi
undertaken
context
drug
repurpos
approach
boost
treatment
strategi
thank
avail
omic
data
implement
biocomput
drug
repurpos
approach
silico
drug
repurpos
hypothesisdriven
approach
take
advantag
use
big
data
identifi
drug
treat
diseas
diseaserel
symptom
process
base
collect
coher
integr
diseas
data
gener
omic
studi
follow
combin
pharmacolog
data
ultim
goal
integr
diseas
network
drug
mode
action
network
silico
drug
repurpos
uniqu
advantag
transform
system
biolog
data
diseas
phenotyp
target
predict
druggabl
target
ideal
provid
fdaapprov
compound
potenti
modulatori
andor
inhibitori
function
immedi
preclin
clinic
test
importantli
data
relev
biolog
clinic
featur
pharmacolog
respons
drug
target
even
drug
offtarget
provid
unexpect
insight
understand
patholog
symptom
possibl
identifi
treatment
comput
tool
hand
theoret
obviou
caution
base
predict
natur
type
studi
could
possibl
gener
hypothesisdriven
computeraid
drug
repurpos
aim
reduc
viru
infect
replic
ii
contrast
infect
advers
symptom
iii
understand
posit
neg
interact
among
treatment
iv
identifi
mechan
viral
infect
suscept
v
predict
potenti
side
effect
treatment
antivir
immun
respons
fact
could
eventu
result
wors
clinic
outcom
possibl
perform
drug
repurpos
abovement
object
uniqu
limit
avail
data
gener
comput
model
diseas
relev
investig
direct
first
step
silico
drug
repurpos
comput
model
viral
pathogenesi
diseaserel
symptom
necessari
thank
releas
genom
sequenc
import
biolog
inform
alreadi
emerg
phylogenet
studi
suggest
natur
origin
highest
nucleotid
sequenc
ident
sarscov
among
six
known
pathogen
hcov
reveal
closest
evolutionari
relationship
sarscov
similarli
sarscov
also
use
protein
viru
receptor
gener
sever
lungassoci
diseas
avail
data
immedi
use
biocomput
drug
repurpos
studi
especi
relat
mechan
hostviru
interact
viru
replic
pend
addit
omic
data
pathogenesi
diseas
model
also
gener
use
molecular
data
studi
alreadi
avail
sarscov
evolutionarili
relat
virus
howev
differ
mortal
rate
diverg
molecular
evolut
clearli
show
uniqu
peculiar
diseas
key
aspect
claim
caution
interpret
silico
drugrepurpos
result
obtain
use
sarscovbas
studi
methodolog
point
view
mani
comput
tool
implement
base
differ
data
type
methodolog
data
type
includ
drug
chemic
structur
physicochem
properti
known
molecular
target
omic
data
type
druginduc
transcript
respons
metabol
simul
methodolog
rang
classic
statist
method
modern
machin
learn
techniqu
comput
drug
repurpos
tool
design
directli
attempt
drugrepurpos
predict
help
process
exampl
tool
base
drugdiseas
associ
network
immedi
suggest
novel
clinic
applic
similar
diseas
phenotyp
wherea
chemic
structur
similar
exploit
priorit
altern
exist
compound
contrast
comput
tool
support
drug
repurpos
process
provid
biolog
insight
drug
mode
action
discov
unknown
molecular
target
exist
drug
gene
express
data
use
character
effect
drug
treatment
reason
systemat
collect
druginduc
wholegenom
express
profil
produc
past
connect
map
cmap
project
latest
releas
within
librari
integr
networkbas
cellular
signatur
linc
project
networkbas
analyt
tool
need
explor
drug
neighborhood
base
similar
induc
transcript
respons
addit
power
comput
tool
predict
sdtnbi
chemmapp
sider
drugbank
wellfulfil
implement
hypothesisdriven
drug
repurpos
number
studi
silico
drug
repurpos
grow
rapidli
among
other
worth
cite
interest
approach
gener
systemspharmacologybas
network
medicin
platform
identifi
interplay
hcovhost
interactom
drug
target
human
proteinprotein
interact
network
identifi
potenti
drug
repurpos
treatment
interact
moreov
virtual
screen
approach
use
investig
fdaapprov
lopac
librari
predict
drug
abl
minim
interact
viral
spike
protein
host
cell
receptor
addit
report
novel
deep
learn
platform
use
identifi
top
potenti
inhibitor
main
proteas
screen
billion
compound
type
report
probabl
repres
tip
iceberg
ongo
drug
repurpos
investig
result
appear
come
week
inde
computeraid
battl
viru
start
also
engag
power
technolog
platform
satisfi
demand
massiv
amount
comput
capac
aim
recent
launch
highperform
comput
consortium
usa
aggreg
comput
capabl
world
power
advanc
comput
help
research
execut
complex
comput
research
program
help
fight
viru
direct
research
silico
drug
repurpos
boost
besid
identifi
novel
hypothesisdriven
drug
treat
patient
comput
approach
could
also
help
understand
current
use
treatment
instanc
antivir
inflammatori
respons
network
would
help
better
deciph
key
mechan
involv
respons
take
advantag
larg
studi
inflammatori
cytokin
avail
biomark
similarli
inspect
drugdrug
network
side
effect
could
predict
whether
specif
drug
propos
investig
would
exacerb
sever
lung
diseas
symptom
instanc
would
help
predict
whether
chloroquin
potenti
reduc
infect
efficaci
could
turn
affect
antivir
immun
respons
target
pathway
crucial
implic
chronic
diseas
elderli
patient
case
could
draw
attent
possibl
chloroquin
offtarget
side
effect
certain
patient
would
limit
treatment
benefit
patient
surviv
final
pandem
scenario
medic
becom
urgent
need
mass
quantiti
could
face
shortag
comput
drug
repurpos
approach
might
assist
quickli
identifi
similar
drug
analog
mode
action
design
altern
synthet
plan
drug
overcom
patent
rout
identifi
inexpens
divers
start
materi
shortag
commonli
use
substrat
could
occur
although
time
efficaci
vaccin
remain
uncertain
vibrant
multidisciplinari
research
oper
alreadi
work
provid
immedi
concret
therapeut
option
base
drug
repurpos
hope
inspir
target
computeraid
drug
repurpos
studi
boost
tailor
effect
therapi
pandem
diseas
